KZR | tickerfilter.com

Fundamental analysis

22%

Profitability 0%

Dept financing 5%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

1.74%

1 Month

-0.17%

3 Months

-13.19%

6 Months

928.07%

1 Year

543.96%

2 Year

13.79%

Key data

Stock price

$5.86

P/E Ratio

0.00

DAY RANGE

$5.76 - $5.96

EPS

-$3.60

52 WEEK RANGE

$0.52 - $8.45

52 WEEK CHANGE

$589.41

MARKET CAP

56.414 M

YIELD

N/A

SHARES OUTSTANDING

72.962 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

1.15

PUBLIC FLOAT

AVERAGE 10 VOLUME

$18,633

AVERAGE 30 VOLUME

$30,632

Company detail

CEO: John Fowler
Region: US
Website: kezarlifesciences.com
Employees: 60
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Kezar Life Sciences, Inc. engages in the discovery and development of novel small molecule therapeutics. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis.

KZR - Kezar Life Sciences, Inc.